10月13日，海正生材跌2.05%，成交额4291.24万元。两融数据显示，当日海正生材获融资买入额481.67 万元，融资偿还760.35万元，融资净买入-278.67万元。截至10月13日，海正生材融资融券余额合计 7054.91万元。 融资方面，海正生材当日融资买入481.67万元。当前融资余额7054.91万元，占流通市值的4.10%，融资 余额超过近一年90%分位水平，处于高位。 责任编辑：小浪快报 资料显示，浙江海正生物材料股份有限公司位于浙江省台州市台州湾新区台州湾大道188号，成立日期 2004年8月26日，上市日期2022年8月16日，公司主营业务涉及聚乳酸的研发、生产及销售。主营业务收 入构成为：纯聚乳酸78.55%，改性聚乳酸20.50%，其他0.96%。 截至6月30日，海正生材股东户数7457.00，较上期增加11.75%；人均流通股15787股，较上期减少 10.51%。2025年1月-6月，海正生材实现营业收入4.08亿元，同比减少5.28%；归母净利润318.15万元， 同比减少87.32%。 分红方面，海正生材A股上市后累计派现4248.71万元。 机构持仓方面，截止2025 ...

Core Viewpoint - On October 10, 2023, Zhejiang Haizheng Biomaterials Co., Ltd. experienced a stock decline of 3.02%, with a trading volume of 54.72 million yuan, indicating potential market volatility and investor sentiment concerns [1]. Financing Summary - On the same day, the company had a financing buy-in amount of 7.32 million yuan and a financing repayment of 3.66 million yuan, resulting in a net financing buy-in of 3.66 million yuan [1]. - As of October 10, the total financing and securities lending balance for the company was 73.34 million yuan, which represents 4.18% of its circulating market value, indicating a high level of financing activity compared to the past year [1]. - The company had no securities lending activity on October 10, with both securities lent and repaid being zero, reflecting a lack of short-selling interest [1]. Business Performance - As of June 30, 2025, the number of shareholders increased by 11.75% to 7,457, while the average circulating shares per person decreased by 10.51% to 15,787 shares [2]. - For the first half of 2025, the company reported a revenue of 408 million yuan, a year-on-year decrease of 5.28%, and a net profit attributable to shareholders of 3.18 million yuan, down 87.32% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 42.49 million yuan in dividends [2]. Shareholding Structure - As of June 30, 2025, among the top ten circulating shareholders, Guangfa Technology Innovation Mixed A (008638) was the fifth largest shareholder, holding 7.05 million shares as a new investor [2].

Group 1 - The core viewpoint of the news is that Zhejiang Haizheng Biomaterials Co., Ltd. has seen a stock price increase of 5.72%, reaching 16.83 CNY per share, with a total market capitalization of 3.41 billion CNY [1] - The company specializes in the research, production, and sales of polylactic acid, with its main revenue sources being pure polylactic acid (78.55%), modified polylactic acid (20.50%), and others (0.96%) [1] - The trading volume for the stock was 95.70 million CNY, with a turnover rate of 4.82% [1] Group 2 - According to data, GF Fund's Guangfa Technology Innovation Mixed A Fund (008638) has entered the top ten circulating shareholders of Haizheng Biomaterials, holding 7.05 million shares, which is 5.99% of the circulating shares [2] - The fund has achieved a year-to-date return of 51.91%, ranking 749 out of 8246 in its category, and a one-year return of 99.24%, ranking 499 out of 8054 [2] - The fund's total scale is 2.657 billion CNY, and since its inception, it has returned 136.12% [2] Group 3 - The fund manager of Guangfa Technology Innovation Mixed A is Wu Yuanyi, who has been in the position for 4 years and 352 days [3] - Under Wu's management, the fund's total asset scale is 20.478 billion CNY, with the best return during his tenure being 107.14% and the worst being -15.24% [3]

Core Viewpoint - The financial performance of Zhejiang Haizheng Biological Materials Co., Ltd. shows a decline in revenue and net profit, indicating potential challenges in the company's operations and market conditions [2]. Financing Summary - On August 28, Haizheng Biological Materials experienced a financing buy-in of 9.87 million yuan, with a net buy of 3.39 million yuan after repayments [1]. - The total financing balance as of August 28 is 41.72 million yuan, accounting for 2.39% of the circulating market value, which is above the 90th percentile of the past year [1]. - The company had no short selling activity on August 28, with a short selling balance of 0.00 yuan, indicating a lack of bearish sentiment [1]. Shareholder and Financial Performance Summary - As of June 30, the number of shareholders increased by 11.75% to 7,457, while the average circulating shares per person decreased by 10.51% to 15,787 shares [2]. - For the first half of 2025, the company reported a revenue of 408 million yuan, a year-on-year decrease of 5.28%, and a net profit of 3.18 million yuan, down 87.32% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 42.49 million yuan in dividends [2]. - Among the top ten circulating shareholders, Guangfa Technology Innovation Mixed A (008638) is the fifth largest, holding 7.05 million shares as a new shareholder [2].